Clik here to view.
J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief
Najat Khan Recursion Pharmaceuticals has poached Najat Khan from Johnson & Johnson, where she led AI efforts at one of healthcare’s giants. Khan will serve as chief R&D and commercial officer,...
View ArticleClik here to view.
Roche's Genentech touts label expansion for blockbuster lung cancer drug...
Roche’s Genentech said that Alecensa scored a label expansion from the FDA, with the drug now approved as an adjuvant treatment following tumor resection in patients with ALK-positive non-small cell...
View ArticleClik here to view.
Rare neuro disorder offers new area for competition, analysts say: #AAN24
An acute competition is emerging among drug developers looking at a rare neurological disorder known as chronic inflammatory demyelinating polyneuropathy, or CIDP, and Wall Street analysts are taking...
View ArticleClik here to view.
Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications...
Will Vertex’s “pipeline-in-a-product” pay off? That’s the bet behind the company’s $4.9 billion acquisition of Alpine Immune Sciences and its mid-stage IgA nephropathy drug, which is designed to...
View ArticleHistogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV...
Plus, news about TScan Therapeutics: Histogen files for Chapter 11 bankruptcy: The biotech, which stopped work in September, filed a petition with the US Bankruptcy Court for the Southern District of...
View ArticleCaliff talks bolstering domestic drug manufacturing, foreign inspections at...
FDA Commissioner Robert Califf told lawmakers he’s ready to work with them to bring more drug manufacturing to the US and laid out the agency’s progress to ramp up overseas inspections at a...
View ArticleSenate Democrats question why Novo discontinued its long-acting insulin Levemir
Novo Nordisk decided to discontinue its long-acting insulin Levemir last November, and three Democrats in the Senate want to know why, laying out their questions in a letter to leaders of the company...
View ArticleCSL Vifor proposes a marketing campaign to settle European Commission...
CSL Vifor is looking to close out a European anti-competitive investigation with a proposed marketing campaign. The European Commission began investigating Vifor Pharma, now CSL Vifor, in June 2022...
View ArticleTakeda wins label expansion for subcutaneous Entyvio, creating 'flexibility'...
Patients taking Takeda’s Entyvio for Crohn’s disease will now have the option of a subcutaneous version. Takeda announced the label expansion on Friday, several months after winning a first approval...
View ArticleNvidia's biotech moment; Regeneron launches venture arm; New GLP-1 player...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
AI drug discovery startup BenevolentAI cuts 30% of staff, closes US office
BenevolentAI is making its second round of layoffs in a year, as the company continues to refine the business strategy around its AI drug discovery platform. Having completed a market assessment,...
View ArticleClik here to view.
FDA approves ImmunityBio's bladder cancer therapy Anktiva
ImmunityBio scored an FDA approval for its once-rejected drug combo for bladder cancer, the biotech announced Monday, sending its stock up nearly 25% in premarket trading. The agency approved the drug...
View ArticleARCH’s Bob Nelsen on launching Xaira with $1B+ to reinvent drug discovery...
In the 37 years since co-founding ARCH Venture Partners, Bob Nelsen has built a reputation for placing head-turning bets on ideas that carry huge amounts of risk and reward. His latest — on AI startup...
View ArticleClik here to view.
Incyte inks $750M deal for immune and neuro biotech Escient
Incyte said it will pay $750 million to buy San Diego biotech Escient Pharmaceuticals and its pipeline of early-stage drug candidates. The deal gives the Delaware-based drugmaker access to once-daily...
View ArticleClik here to view.
Inside Vertex, Alpine's negotiations leading to $4.9B M&A deal
Jeffrey Leiden wanted Alpine. The Vertex chair, who had led early development of the world’s top-selling medicine while at Abbott in the 2000s, had his eyes on Alpine Immune Sciences’ investigational...
View ArticleLilly nabs injectable medicines facility from Nexus Pharma
To help meet the heightened demand for its injectable products, Eli Lilly is acquiring a facility from Nexus Pharmaceuticals, with production anticipated to start at the end of next year. Lilly will...
View ArticleMarc Tessier-Lavigne on leaving Stanford and joining AI mega-startup Xaira
Earlier Tuesday, Endpoints News reported that former Stanford president Marc Tessier-Lavigne will lead one of biotech’s biggest-ever startup launches: Xaira Therapeutics, which has secured over $1...
View ArticleClik here to view.
Pascal Soriot’s been pushing for US-sized CEO pay for more than a decade. Now...
Bioregnum Opinion Column by John Carroll Back in 2013, Pascal Soriot’s first full year at the helm of a tottering AstraZeneca, he landed a pay package worth about $5.5 million. By pharma CEO standards,...
View ArticleClik here to view.
Neurocrine’s depression drug passes Phase 2 trial
Neurocrine Biosciences reported that its pill for major depressive disorder reduced scores on a depression severity scale at about one month in a Phase 2 trial. In the SAVITRI study, 183 adult...
View ArticleClik here to view.
Pharma companies tone down ESG mentions, but not ambitions
Pharma companies are scaling back the use of terms like “ESG” and “diversity, equity and inclusion,” much like companies in other industries. In pharma 10-K filings, mentions of ESG, sustainability, or...
View Article